Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385667310> ?p ?o ?g. }
Showing items 1 to 94 of
94
with 100 items per page.
- W4385667310 endingPage "e3064078" @default.
- W4385667310 startingPage "e3064078" @default.
- W4385667310 abstract "Background: T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy with a dismal prognosis related to refractory/relapsing diseases, raising the need for new targeted-therapies. Activating mutations of the IL7-receptor pathway genes (IL7Rp) play a proven leukemia-supportive role in T-ALL. JAK-inhibitors (JAKi) such as ruxolitinib have recently demonstrated preclinical efficacy. However, prediction markers for sensitivity to JAKi are still lacking. Aims: We aimed to provide a biological rationale to address the question of ‘who and how I treat’ with JAK-inhibitors in T-ALL. We thus sought to determine the extent of the IL7 oncogenic addiction in T-ALL and the patient categories who could benefit from JAKi. Methods: We analyzed a large cohort of primary T-ALL samples (n=200) for IL7R-expression (CD127) by flow-cytometry and IL7Rp-mutations using NGS. We compared the characteristics of the identified subgroups from an epigenetic perspective using Chip-Seq (n=26) and EPIC-array (n=26), and at the transcriptomic level (n=85) using RNA-seq. We also investigated their IL7Rp functional properties using pSTAT5 flow assay with (w) or without (w/o) IL7 and w or w/o ruxolitinib in primary derived xenografts (PDX, n=46). Finally, we used an apoptotic assay (Annexin V/ Propidium iodide) to evaluate the cytotoxic reponse to JAKi +/- venetoclax, an inhibitor of BCL2 which is a downstream target of the IL7Rp. Results: We show that IL7R (CD127) expression is more frequent (~70%) than IL7Rp-mutations (~30%) in adult T-ALL (n=200). This delineated 3 T-ALL categories including the so-called non-expressers (no IL7R-expression/IL7Rp-mutation), expressers (IL7R-expression without IL7Rp-mutation) and mutants (IL7Rp-mutations). Noteworthy, these categories were highly preserved from diagnostic to relapse in a cohort of 29 relapsing-T-ALL. Integrative multi-omics analysis outlined IL7R-deregulation in virtually all 3 T-ALL categories: at the epigenetic-level in non-expressers (hypermethylation), genetic-level in mutants (mutation(s)), and post-transcriptional level in expressers (ectopic expression). We then questionned the functionality and druggability of IL7Rp in each of the 3 T-ALL categories by investigating their response to IL7 and IL7+JAKi. Ex-vivo data using PDX support that IL7Rp is functional whenever the IL7R is expressed, regardless of the IL7Rp mutational status. Consequently, ruxolitinib impaired T-ALL survival in both expressers and mutants. Interestingly, we show that expressers displayed ectopic IL7R-expression and IL7Rp-addiction conferring a deeper sensitivity to ruxolitinib. Conversely, mutants were more sensitive to venetoclax than expressers. Overall, combination of ruxolitinib and venetoclax resulted in synergistic effects in both groups. Finally, we illustrate the clinical relevance of this association by reporting achievement of complete remission in two patients with refractory/relapsed-T-ALL that enabled bridge-to-transplant. Summary/Conclusion: Altogether, this study provides valuable information to optimize translation of JAKi and venetoclax to clinics for T-ALL patients with relapse who need therapeutics to bridge to transplant. This treatment protocol may benefit to a larger group of patients who may be selected with an easily applicable flow-cytometry-based companion test. IL7R-expression can be used as a biomarker for sensitivity to JAK-inhibition, thereby expanding the fraction of T-ALL patients eligible to JAKi up to nearly ~70% of T-ALL. Keywords: Signaling, T-ALL, Ruxolitinib, Targeted therapy" @default.
- W4385667310 created "2023-08-09" @default.
- W4385667310 creator A5007415374 @default.
- W4385667310 creator A5024312576 @default.
- W4385667310 creator A5031261793 @default.
- W4385667310 creator A5033072030 @default.
- W4385667310 creator A5035109792 @default.
- W4385667310 creator A5037286573 @default.
- W4385667310 creator A5037596808 @default.
- W4385667310 creator A5040592419 @default.
- W4385667310 creator A5046761978 @default.
- W4385667310 creator A5052564121 @default.
- W4385667310 creator A5057234657 @default.
- W4385667310 creator A5059468087 @default.
- W4385667310 creator A5059743121 @default.
- W4385667310 creator A5067808997 @default.
- W4385667310 creator A5069499304 @default.
- W4385667310 creator A5076973611 @default.
- W4385667310 creator A5086254154 @default.
- W4385667310 creator A5091488339 @default.
- W4385667310 date "2023-08-01" @default.
- W4385667310 modified "2023-10-17" @default.
- W4385667310 title "P319: IL7-RECEPTOR EXPRESSION IS FREQUENT IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND PREDICTS SENSITIVITY TO JAK-INHIBITION" @default.
- W4385667310 doi "https://doi.org/10.1097/01.hs9.0000968188.30640.78" @default.
- W4385667310 hasPublicationYear "2023" @default.
- W4385667310 type Work @default.
- W4385667310 citedByCount "0" @default.
- W4385667310 crossrefType "journal-article" @default.
- W4385667310 hasAuthorship W4385667310A5007415374 @default.
- W4385667310 hasAuthorship W4385667310A5024312576 @default.
- W4385667310 hasAuthorship W4385667310A5031261793 @default.
- W4385667310 hasAuthorship W4385667310A5033072030 @default.
- W4385667310 hasAuthorship W4385667310A5035109792 @default.
- W4385667310 hasAuthorship W4385667310A5037286573 @default.
- W4385667310 hasAuthorship W4385667310A5037596808 @default.
- W4385667310 hasAuthorship W4385667310A5040592419 @default.
- W4385667310 hasAuthorship W4385667310A5046761978 @default.
- W4385667310 hasAuthorship W4385667310A5052564121 @default.
- W4385667310 hasAuthorship W4385667310A5057234657 @default.
- W4385667310 hasAuthorship W4385667310A5059468087 @default.
- W4385667310 hasAuthorship W4385667310A5059743121 @default.
- W4385667310 hasAuthorship W4385667310A5067808997 @default.
- W4385667310 hasAuthorship W4385667310A5069499304 @default.
- W4385667310 hasAuthorship W4385667310A5076973611 @default.
- W4385667310 hasAuthorship W4385667310A5086254154 @default.
- W4385667310 hasAuthorship W4385667310A5091488339 @default.
- W4385667310 hasBestOaLocation W43856673101 @default.
- W4385667310 hasConcept C123982805 @default.
- W4385667310 hasConcept C126322002 @default.
- W4385667310 hasConcept C143998085 @default.
- W4385667310 hasConcept C203014093 @default.
- W4385667310 hasConcept C2776090121 @default.
- W4385667310 hasConcept C2776112149 @default.
- W4385667310 hasConcept C2778461978 @default.
- W4385667310 hasConcept C2780007613 @default.
- W4385667310 hasConcept C2780076729 @default.
- W4385667310 hasConcept C502942594 @default.
- W4385667310 hasConcept C71924100 @default.
- W4385667310 hasConcept C79484868 @default.
- W4385667310 hasConcept C8891405 @default.
- W4385667310 hasConceptScore W4385667310C123982805 @default.
- W4385667310 hasConceptScore W4385667310C126322002 @default.
- W4385667310 hasConceptScore W4385667310C143998085 @default.
- W4385667310 hasConceptScore W4385667310C203014093 @default.
- W4385667310 hasConceptScore W4385667310C2776090121 @default.
- W4385667310 hasConceptScore W4385667310C2776112149 @default.
- W4385667310 hasConceptScore W4385667310C2778461978 @default.
- W4385667310 hasConceptScore W4385667310C2780007613 @default.
- W4385667310 hasConceptScore W4385667310C2780076729 @default.
- W4385667310 hasConceptScore W4385667310C502942594 @default.
- W4385667310 hasConceptScore W4385667310C71924100 @default.
- W4385667310 hasConceptScore W4385667310C79484868 @default.
- W4385667310 hasConceptScore W4385667310C8891405 @default.
- W4385667310 hasIssue "S3" @default.
- W4385667310 hasLocation W43856673101 @default.
- W4385667310 hasLocation W43856673102 @default.
- W4385667310 hasOpenAccess W4385667310 @default.
- W4385667310 hasPrimaryLocation W43856673101 @default.
- W4385667310 hasRelatedWork W1531655234 @default.
- W4385667310 hasRelatedWork W1816675776 @default.
- W4385667310 hasRelatedWork W1985986955 @default.
- W4385667310 hasRelatedWork W2044053906 @default.
- W4385667310 hasRelatedWork W2195061194 @default.
- W4385667310 hasRelatedWork W2276761736 @default.
- W4385667310 hasRelatedWork W2993344364 @default.
- W4385667310 hasRelatedWork W3029773958 @default.
- W4385667310 hasRelatedWork W3207807551 @default.
- W4385667310 hasRelatedWork W4220929633 @default.
- W4385667310 hasVolume "7" @default.
- W4385667310 isParatext "false" @default.
- W4385667310 isRetracted "false" @default.
- W4385667310 workType "article" @default.